Werewolf Therapeutics (HOWL) Retained Earnings (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Retained Earnings of $501.6 million for Q2 2026, up 1.92% year-over-year from $492.1 million in Q2 2025, and little changed on a QoQ basis from $501.1 million in Q1 2026.
Werewolf Therapeutics (HOWL) Retained Earnings (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Retained Earnings for 7 years, with the latest figure at $501.6 million in Q2 2026.
- Retained Earnings for Q2 2026 came in at $501.6 million, up 1.92% year-over-year; the trailing twelve-month figure through Jun 2026 was $501.6 million (up 1.92% YoY), and the FY2025 annual result was $500.2 million, up 2.51% from the prior year.
- Retained Earnings steadied at $501.6 million in Q2 2026, from $501.1 million in the prior quarter.
- Over five years, Retained Earnings peaked at $501.6 million in Q2 2026 and troughed at $407.6 million in Q1 2022.
- A 5-year average of $465.0 million and a median of $479.7 million in 2024 frame the typical range for Retained Earnings.
- The widest annual swing landed in 2022, when Retained Earnings jumped 365.07%; it then grew 1.92% in 2026.
- A 5-year view of Retained Earnings shows it stood at $429.0 million in 2022, then grew by 6.15% to $455.4 million in 2023, then gained by 7.14% to $488.0 million in 2024, then rose by 2.51% to $500.2 million in 2025, then advanced by 0.27% to $501.6 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were $501.6 million in Q2 2026, $501.1 million in Q1 2026, and $500.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | 501.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 501.56 Mn |
| Mar 31, 2026 | 501.14 Mn |
| Dec 31, 2025 | 500.21 Mn |
| Sep 30, 2025 | 496.64 Mn |
| Jun 30, 2025 | -450.66 Mn |
| Mar 31, 2025 | -432.68 Mn |
| Dec 31, 2024 | 487.97 Mn |
| Sep 30, 2024 | -394.19 Mn |
| Jun 30, 2024 | -377.52 Mn |
| Mar 31, 2024 | -360.27 Mn |
| Dec 31, 2023 | -344.07 Mn |
| Sep 30, 2023 | -332.07 Mn |
| Jun 30, 2023 | -323.79 Mn |
| Mar 31, 2023 | 439.76 Mn |
| Dec 31, 2022 | 429.04 Mn |
| Sep 30, 2022 | -294.78 Mn |
| Jun 30, 2022 | -282.83 Mn |
| Mar 31, 2022 | 407.55 Mn |
| Dec 31, 2021 | -252.90 Mn |
| Sep 30, 2021 | -235.03 Mn |